Furthermore, Allison et al. observed differential changes in CSF levels of C-C motif chemokine ligand 5 (CCL5) and IL-1 receptor antagonist (IL-1ra) before and after nusinersen treatment in SMA patients. This evidence concerns the gene CCL5 and proximal spinal muscular atrophy.